GetTopicDetailResponse(id=604ce55397b, topicName=突破性療法指定, introduction=突破性療法指定, content=null, image=null, comments=4, allHits=1115, url=https://h5.medsci.cn/topic?id=75539, type=0, isShow=1, status=1, isAdmin=null, adminId=1, adminEncryptionId=1eae1, adminName=小M, createdBy=null, createdName=, createdAvatar=, createdTime=Fri May 29 21:19:53 CST 2020, time=2020-05-29, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=94149, tagList=[TagDto(tagId=94149, tagName=突破性療法指定)], ipAttribution=, topicAdmin=1, lengthMark=0)
[GetTopicListResponse(id=1986466, encodeId=9cd7198646645, content=<a href='/topic/show?id=604ce55397b' target=_blank style='color:#2F92EE;'>#突破性療法指定#</a>, objectTitle=Janssen宣布FDA授予其PARP抑制劑Niraparib治療轉(zhuǎn)移性去勢(shì)抵抗性前列腺癌的突破性療法指定, objectType=article, longId=180512, objectId=112b180512c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=112b180512c6, replyNumber=0, likeNumber=81, createdTime=2020-04-29, rootId=0, userName=Boyinsh, userId=726030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=112b180512c6, moduleTitle=Janssen宣布FDA授予其PARP抑制劑Niraparib治療轉(zhuǎn)移性去勢(shì)抵抗性前列腺癌的突破性療法指定, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=112b180512c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1986465, encodeId=65a01986465d9, content=<a href='/topic/show?id=604ce55397b' target=_blank style='color:#2F92EE;'>#突破性療法指定#</a>, objectTitle=Achillion的D因子抑制劑Danicopan治療陣發(fā)性夜間血紅蛋白尿，獲得FDA突破性療法指定, objectType=article, longId=180107, objectId=1e3218010eb7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1e3218010eb7, replyNumber=0, likeNumber=98, createdTime=2020-04-11, rootId=0, userName=Boyinsh, userId=726030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1e3218010eb7, moduleTitle=Achillion的D因子抑制劑Danicopan治療陣發(fā)性夜間血紅蛋白尿，獲得FDA突破性療法指定, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=1e3218010eb7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1986464, encodeId=bfdd1986464e9, content=<a href='/topic/show?id=604ce55397b' target=_blank style='color:#2F92EE;'>#突破性療法指定#</a>, objectTitle=Janssen的呼吸道合胞病毒RSV疫苗被FDA授予突破性療法指定, objectType=article, longId=178985, objectId=41461e898555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41461e898555, replyNumber=0, likeNumber=90, createdTime=2020-05-02, rootId=0, userName=Boyinsh, userId=726030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41461e898555, moduleTitle=Janssen的呼吸道合胞病毒RSV疫苗被FDA授予突破性療法指定, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=41461e898555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1986463, encodeId=b03a1986463c6, content=<a href='/topic/show?id=604ce55397b' target=_blank style='color:#2F92EE;'>#突破性療法指定#</a>, objectTitle=治療大 B 細(xì)胞淋巴瘤又一單抗獲 FDA 突破性療法指定, objectType=article, longId=117910, objectId=9e7d11e910f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9e7d11e910f4, replyNumber=0, likeNumber=75, createdTime=2017-12-21, rootId=0, userName=Boyinsh, userId=726030, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9e7d11e910f4, moduleTitle=治療大 B 細(xì)胞淋巴瘤又一單抗獲 FDA 突破性療法指定, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=9e7d11e910f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)]
梅斯話題小助手
2020-05-29
